Generate the optimized scFvs to yield CAR-T cells with robust anti-tumor effect
Location: Japan, Matsuyama
Investors 3
| Date | Name | Website |
| 25.11.2021 | Real Tech ... | en.realtec... |
| 31.01.2025 | Kobe Unive... | kuc.vc |
| - | Iyogin Cap... | iyo-capita... |
Mentions in press and media 2
| Date | Title | Description |
| 05.05.2025 | Genezen and Optieum Biotechnologies Partner to Support cGMP Manufacturing of Groundbreaking CAR-T Therapy for Glioblastoma | Collaboration supports manufacture of the OPTF01 product to Drive Next-Generation Chimeric Antigen Receptor T Cell (CAR-T) Development INDIANAPOLIS and EHIME, Japan, May 5, 2025 /PRNewswire/ -- Genezen, a leading viral vector Contract Devel... |
| - | Optieum Biotechnologies | “Generate the optimized scFvs to yield CAR-T cells with robust anti-tumor effect” |